Cardiff Oncology, Inc. cash flow to debt ratio of -4.56K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cardiff Oncology, Inc.'s free cash flow has decreased 0.51% from $-37.77M last year to $-37.97M, signaling decreasing performance

Cardiff Oncology, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Cardiff Oncology, Inc.'s debt has increased relative to shareholder equity from 0.02 last year to 0.02 today, signaling weakened financials

Cardiff Oncology, Inc. has negative EBITDA, making leverage ratio unreliable

Cardiff Oncology, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Cardiff Oncology, Inc.'s profit margin has decreased (28.18%) in the last year from -6.65K% to -8.53K%, signaling decreasing performance

Cardiff Oncology, Inc.'s short-term assets of $60.13M exceed its short-term liabilities of $16.39M

Cardiff Oncology, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cardiff Oncology, Inc.'s return on equity of -95.50%, is lower than 15.00%, indicating bad performance

Cardiff Oncology, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cardiff Oncology, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Cardiff Oncology, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Cardiff Oncology, Inc. has negative free cash flow, indicating cash burn

Cardiff Oncology, Inc.'s yearly earnings has decreased 0.92% since last year from $-45.43M to $-45.85M, signaling decreasing performance

Cardiff Oncology, Inc.'s yearly revenue has decreased -13.18% since last year from $683.00K to $593.00K, signaling decreasing performance

ROIC -134.15% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cardiff Oncology, Inc.'s 3-year revenue CAGR of 15.39% is positive, indicating growing revenue over the past 3 years

Cardiff Oncology, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Cardiff Oncology, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Cardiff Oncology, Inc. has insufficient data to evaluate this check.

Cardiff Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cardiff Oncology, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cardiff Oncology, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cardiff Oncology, Inc. has insufficient data to evaluate this check.

Cardiff Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cardiff Oncology, Inc. has a price-to-book ratio of 2.46x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Cardiff Oncology, Inc. has a price-to-sales ratio of 162.79x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue